North America Intravenous Immunoglobulin Market is expected to reach US$ 8,747.81 million by 2030

IgG to Dominate Intravenous Immunoglobulin Market Based on Type 

According to our new research study on "North America Intravenous Immunoglobulin Market Forecast to 2030 – Regional Analysis – by Type, Application, Distribution Channel, and End User," the intravenous immunoglobulin market was valued at US$ 5,042.91 million in 2022 and is projected to reach US$ 8,747.81 million by 2030. It is estimated to register a CAGR of 7.1% during 2022–2030.

The North America intravenous immunoglobulin market, by type, is segmented into IgG, IgA, IgM, and others. In 2022, the IgG segment held the largest share and is expected to record the fastest CAGR during 2022–2030. Based on application, the North America intravenous immunoglobulin market is classified into immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, idiopathic thrombocytopenic purpura, multifocal motor neuropathy, hypogammaglobulinemia, Guillain-Barre syndrome, specific antibody deficiency, inflammatory myopathies, myasthenia gravis, and others. In 2022, the immunodeficiency diseases segment held the largest market share, and it is expected to register the highest CAGR during 2022–2030. The North America intravenous immunoglobulin market is segmented based on distribution channels into hospital pharmacy, retail pharmacy, and others. In 2022, the hospital pharmacy segment held the largest share, and it is expected to record the fastest CAGR during 2022–2030. Based on end user, the North America intravenous immunoglobulin market is classified into hospitals, specialty clinics, and others. In 2022, the hospitals segment held the largest share, and it is expected to register the fastest CAGR during 2022–2030. Based on country, the North America intravenous immunoglobulin market is segmented into the US, Canada, and Mexico. In 2022, the US held the largest market share. The intravenous immunoglobulins market in Canada is expected to grow at the highest CAGR during 2022–2030.

Increase in Use of Immunoglobulins Bolsters North America Intravenous Immunoglobulins Market

Plasma-derived immunoglobulins are used for treating autoimmune and inflammatory disorders, among others. In addition to autoimmune and acute inflammatory conditions, primary immune deficiency disease (PIDD), chronic inflammatory demyelinating polyneuropathy (CIDP), and multifocal motor neuropathy (MMN) are the chronic and acute conditions that are treated with immunoglobulins. Immunoglobulins are also increasingly used to manage infectious diseases, dermatological conditions, rheumatological/nephrological conditions, and heart disease. Thus, the demand for intravenous immunoglobulins is rising with the surging use of these antibodies for treating various conditions.

Takeda Pharmaceutical Co Ltd; Grifols SA; Pfizer Inc.; ADMA Biologics, Inc.; Bio Products Laboratory Ltd; Octapharma AG; Kedrion SpA.; CSL Ltd.; LFB Group; and Prothya Biosolutions B.V are among the leading companies operating in the intravenous immunoglobulin market.

Contact Us
Contact Us: The Insight Partners 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com